Skip to main content
SpringerLink
Log in

Use of β-Blockers in Atrial Fibrillation

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Atrial fibrillation is the most common arrhythmia in the general population and is frequently associated with organic heart disease. β-adrenoceptor antagonists (β-blockers) are very effective in preventing atrial fibrillation after coronary artery bypass surgery It has been shown recently that the β-blocker metoprolol controlled release/extended release (CR/XL) is also effective in maintaining sinus rhythm after conversion of atrial fibrillation. There is concern that class I antiarrhythmic drugs, such as quinidine, disopyramide, and flecainide in particular, may increase mortality. The risk of proarrhythmia associated with β-blocker treatment is very low. Therefore β—blockers, such as metoprolol CR/XL, may be the first line of treatment to maintain sinus rhythm, especially after myocardial infarction and in patients with chronic heart failure and in those with arterial hypertension.

In patients with persistent atrial fibrillation, AV-nodal conduction-slowing drugs, such as calcium channel antagnoists and β-blockers are used to control the ventricular rate during atrial fibrillation. Several studies clearly show that β-blockers alone, or in combination with digoxin are very effective in controlling the ventricular rate at rest and during exercise, β-blockers are effective in maintaining sinus rhythm and controlling the ventricular rate during atrial fibrillation. Given these effects and their favorable effects on mortality, β-blockers should be considered as first-line agents in the management of patients with atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22

    Article  PubMed  CAS  Google Scholar 

  2. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469–73

    Article  PubMed  CAS  Google Scholar 

  3. Benjamin EJ, Levy D, Vaziri EM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994; 271: 840–4

    Article  PubMed  CAS  Google Scholar 

  4. Atrial Fibrillation Investigators: risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57

    Article  Google Scholar 

  5. Carlsson J, Neuzner J, Rosenberg YD. Therapy of atrial fibrillation: rhythm control versus rate control. Pacing Clin Electrophysiol 2000; 23: 891–903

    Article  PubMed  CAS  Google Scholar 

  6. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation. Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789–94

    Article  PubMed  CAS  Google Scholar 

  7. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455–61

    Article  PubMed  CAS  Google Scholar 

  8. Kowey PR, Taylor JE, Rials SJ, et al. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69: 863–5

    Article  Google Scholar 

  9. Fuchs T, Podrid PJ. Pharmacologic therapy for reversion of atrial fibrillation and maintenance of sinus rhythm. In: Falk RH, Podrid PJ, editors. Atrial fibrillation. Mechanisms and management. New York: Raven Press, 1992: 233–51

    Google Scholar 

  10. Juul-Möller S, Edvardsson N, Rehnquist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932–9

    Article  PubMed  Google Scholar 

  11. Nattel S, Feder-Elituv R, Matthews C, et al. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. J Am Coll Cardiol 1989; 13: 1190–4

    Article  PubMed  CAS  Google Scholar 

  12. Edvardsson N, Huikkuri H, Kennebäck G, et al. Antiarrhythmic efficacy by a class III agent with and without betablockade in chronic atrial fibrillation — a double blind randomized comparison of d,l sotalol, d sotalol and placebo [abstract]. J Am Coll Cardiol 1996; 27 Suppl.; 46A

    Article  Google Scholar 

  13. Funck-Brentano C, Kibleur Y, Le Coz F, et al. Rate dependence of sotalol induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991; 83: 536–45

    Article  PubMed  CAS  Google Scholar 

  14. Plewan A, Lehman G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrail fibrillation: sotalol vs bisoprolol. Eur Heart J 2001: 22(16): 1504–10

    Article  PubMed  CAS  Google Scholar 

  15. Steeds RP, Birchall AS, Smith M, et al. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999; 82: 170–5

    PubMed  CAS  Google Scholar 

  16. Fischer F, Schwacke H, Rameken M, et al. Frequency of symptomatic recurrences of atrial fibrillation after successful electrical cardioversion of atrial fibrillation in patients treated with metoprolol in comparison to sotalol. J Am Coll Cardiol 2001; 37 Suppl.: 648A

    Google Scholar 

  17. Kühlkamp V, Schirdewan A, Stangl K, et al. Use of Metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized double blind placebo controlled study. J Am Coll Cardiol 2000; 36: 139–46

    Article  PubMed  Google Scholar 

  18. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879–86

    Article  PubMed  CAS  Google Scholar 

  19. Campbell DL, Rasmusson RL, Comer MB, et al. The cardiac calcium-independent outward potassium current: kinetics, molecular properties, and role in ventricular repolarization. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology. from cell to bedside. Philadelphia: W.B.Saunders Company, 1995: 83–96

    Google Scholar 

  20. Daoud EG, Bogun F, Harvey M, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600–6

    Article  PubMed  CAS  Google Scholar 

  21. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061–76

    Article  PubMed  CAS  Google Scholar 

  22. Li G-R, Feng J, Wang Z, et al. Adrenergic modulation of ultrarapid delayed rectifier K current in human atrial myocytes. Circ Res 1996; 78: 903–15

    Article  PubMed  CAS  Google Scholar 

  23. Crijns HJGM, van Gelder IC, Lie KI. Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter. Eur Heart J 1994: 15 Suppl. A: 17–21

    PubMed  Google Scholar 

  24. Page RL. Beta-blockers for atrial fibrillation: must we consider asymptomatic arrhythmias? J Am Coll Cardiol 2000; 36: 147–50

    Article  PubMed  CAS  Google Scholar 

  25. Fetsch T, Burschel G, Breithardt G, et al. Die medikamentose Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC-Studie. Z Kardiol 1999; 88: 195–207

    Article  PubMed  CAS  Google Scholar 

  26. Fetsch T, Breithardt G, Engberding R, et al. Prevention of atrial fibrillation after cardioversion — results of PAFAC Trial [abstract]. Circulation 2001; 104 Suppl. II: 699

    Google Scholar 

  27. Fetsch T, Breithardt G, Engberding R, et al. Can we believe in symptoms for detention of atrial fibrillation in clinical routine? Results of the PAFAC trial. [abstract]. Circulation 2001; 104 Suppl. II: 699

    Google Scholar 

  28. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913–20

    Article  PubMed  CAS  Google Scholar 

  29. Singh SN, Fletcher RD, Gross Fisher S, et al. The Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82

    Article  PubMed  CAS  Google Scholar 

  30. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular depolarisations: CAMIAT. Lancet 1997; 349: 675–82

    Article  PubMed  CAS  Google Scholar 

  31. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–74

    Article  PubMed  CAS  Google Scholar 

  32. Antman EM, Beamer AD, Cantillon CO, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698–707

    Article  PubMed  CAS  Google Scholar 

  33. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983; 106: 870–6

    Article  PubMed  CAS  Google Scholar 

  34. Chin SH, Sager PT, Stevenson WG, et al. Long term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76: 47–50

    Article  Google Scholar 

  35. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63: 925–9

    Article  PubMed  CAS  Google Scholar 

  36. Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J 1993; 126: 368–74

    Article  PubMed  CAS  Google Scholar 

  37. Rawles JM. What is meant by a ‘controlled’ ventricular rate in atrial fibrillation? Br Heart J 1990; 63: 157–61

    Article  PubMed  CAS  Google Scholar 

  38. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570–3

    Article  PubMed  CAS  Google Scholar 

  39. Falk RH. Control of the ventricular rate in atrial fibrillation. Falk RH, Podrid (eds) PJ. Atrial fibrillation. mechanisms and management 1992 New York: Raven Press, 1992: 255–82

    Google Scholar 

  40. Saksena S, Klein GJ, Kowey PR, et al. Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias. Am J Cardiol 1987; 59: 307–12

    Article  PubMed  CAS  Google Scholar 

  41. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984; 108: 1121–7

    Article  PubMed  CAS  Google Scholar 

  42. Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 1985; 110: 913–22

    Article  PubMed  CAS  Google Scholar 

  43. Atwood JE, Sullivan MJ, Forbes SM, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10: 314–20

    Article  PubMed  CAS  Google Scholar 

  44. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995; 75: 88–90

    Article  PubMed  CAS  Google Scholar 

  45. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304–10

    Article  PubMed  CAS  Google Scholar 

  46. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33

    Article  PubMed  CAS  Google Scholar 

  47. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators: atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. Am J Cardiol 1997; 79: 1198–202

    Article  Google Scholar 

  48. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ editors. Atrial fibrillation. mechanisms and management. New York: Raven Press, 1992: 25

    Google Scholar 

  49. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106–16

    Article  PubMed  CAS  Google Scholar 

  50. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian flecainide multicenter study group. Am J Cardiol 1991; 67: 713–7

    Article  PubMed  CAS  Google Scholar 

  51. Härtel G, Louhija A, Konttinen A, et al. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 1974; 15:551–5

    PubMed  Google Scholar 

  52. Karlson BW, Torstensson I, Abjorn C, et al. Disopyramide in the maintenance of sinus rhythm after electroversion of atrial fibrillation — a placebo controlled one year follow-up study. Eur Heart J 1988; 9: 284–90

    PubMed  CAS  Google Scholar 

  53. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550–7

    Google Scholar 

  54. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557–70

    Article  PubMed  CAS  Google Scholar 

  55. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized placebo-controlled crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114: 539–44

    PubMed  CAS  Google Scholar 

  56. Torp-Pedersen T, Moeller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857–65

    Article  PubMed  CAS  Google Scholar 

  57. Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation Dofetilide) study [abstract]. Circulation 1998; Suppl. 1: 633

    Google Scholar 

  58. Pritchett ELC, Page RL, Connolly SJ, et al. ASAP Investigators: azimilide treatment of atrial fibrillation. Circulation 1998; 98 Suppl. 1–633

    Article  Google Scholar 

  59. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32

    Article  PubMed  CAS  Google Scholar 

  60. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141–50

    PubMed  CAS  Google Scholar 

  61. Stevenson WG, Stevenson LW, Middlekauf HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458–63

    Article  PubMed  CAS  Google Scholar 

  62. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators: Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation 1997; 96: 2625–32

    Article  Google Scholar 

  63. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J 1995; 130: 1094–106

    Article  PubMed  CAS  Google Scholar 

  64. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13

    Article  Google Scholar 

  65. MERIT-HF Investigator Group. Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7

    Article  Google Scholar 

  66. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992; 13: 28–32

    PubMed  CAS  Google Scholar 

  67. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151–8

    PubMed  CAS  Google Scholar 

  68. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III der Eberhard-Karls-Universität Tübingen, Tübingen, 72076, Germany

    Volker Kühlkamp, Ralph Bosch, Christian Mewis & Ludger Seipel

Authors
  1. Volker Kühlkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Mewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ludger Seipel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Volker Kühlkamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kühlkamp, V., Bosch, R., Mewis, C. et al. Use of β-Blockers in Atrial Fibrillation. Am J Cardiovasc Drugs 2, 37–42 (2002). https://doi.org/10.2165/00129784-200202010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200202010-00005

Keywords

Search

Navigation